研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]The First Affiliated Hospital of Anhui Medical University[3]Beijing Cancer Hospital[4]The sixth affliated hospital of Sun Yat-Sen Unversity[5]Harbin Tumor Hospital[6]Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology Wuhan, Hubei, China[7]Peking University Cancer Hospital & Institute
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
